OBXHealthcare · Biotechnology

OBX Stock Forecast: Obsidian Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026

$15

+1.86% on the day

The 5 Wall Street analysts covering Obsidian Therapeutics, Inc. hold a median 12-month price target of $42 — +184.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 31 Oct 2026 — in the upper half.

Market cap

$913.6M

Ticker Nerd rank

62/ 100

Median analyst target

$42

Analysts covering

Total return, dividends reinvested

+5.8%

+7.7%

From high

−57.7%

From low

+25.7%

$12

$35

Range since 29 July 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

OBX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Obsidian Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026

62/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance

100

Value

Momentum

Quality

Growth

Size

Revisions

Accruals

Volatility

Issuance (100): The share count has been shrinking and the company is not leaning on new borrowing.

Volatility (10): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OBX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OBX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 29 July 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts

5 Buy0 Hold0 Sell

Low $32Median $42High $43

The green dot is the last close — the median target sits +184.0% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
22 Sept 2026	Leerink Partners	Initiates	Outperform	$32
9 Sept 2026	William Blair	Initiates	Outperform	—
9 Sept 2026	William Blair	Initiates	Outperform	—
18 Aug 2026	LifeSci Capital	Initiates	Outperform	—
5 Aug 2026	Piper Sandler	Initiates	Overweight	—
5 Aug 2026	Piper Sandler	Initiates	Overweight	$42

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

OBX appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

OBX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

OBX vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OBX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year

Analysts raising

Analysts cutting

Fundamentals

Obsidian Therapeutics, Inc. (OBX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −9.0×
Price / sales: —
Price / book: −3.3×
EV / EBITDA: −12.6×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: 37.8%
Return on assets: −113.6%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Obsidian Therapeutics, Inc. (OBX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Obsidian Therapeutics, Inc. has a market value of $913.6M and an enterprise value of $1.2B.
Shares outstanding: 61.6M.
Trailing P/E: −9.0×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Obsidian Therapeutics, Inc. employs 87 people.

market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

OBX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
OBXObsidian Therapeutics, Inc.	$913.6M	62
KURAKura Oncology, Inc.	$910.7M	75
GLUEMonte Rosa Therapeutics, Inc.	$909.0M	65
ODTXOdyssey Therapeutics, Inc.	$921.8M	0
CGEMCullinan Therapeutics, Inc.	$923.7M	72
JBIOJade Biosciences, Inc.	$894.2M	26
LTGOLatigo Biotherapeutics, Inc.	$882.2M	1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Obsidian Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OBX news & analysis

Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting

Business Wire · 2 Oct 2026positive

Obsidian Therapeutics announced it will present a poster of updated data from its Phase 1 first-in-human study and Phase 1/2 Agni-01 multicenter study of amsoki-cel (OBX-115) in patients with immune-checkpoint inhibitor-resistant advanced melanoma at the SITC 2026 Annual Meeting. The presentation covers patients from the single-center FIH study and the multicenter trial.

Why it matters — OBX watchers would care because this represents the latest clinical data update for amsoki-cel, the company's lead engineered TIL cell therapy candidate, in the hard-to-treat ICI-resistant advanced melanoma setting.

Obsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For Error

Seeking Alpha · 11 Sept 2026negative

Seeking Alpha rates Obsidian Therapeutics as Hold, citing overvaluation despite its promising cell therapy technology for solid tumors. Lead asset OBX-115 shows strong early efficacy and safety in advanced melanoma but remains in Phase 1/2, while the ~$1.1 billion market cap and ~$17.00 trading price exceed its risk-adjusted fair value of $10.16 per share.

Why it matters — An OBX watcher would care because the analysis highlights that the current valuation leaves little room for error given OBX-115's early-stage status, suggesting limited upside at present prices.

Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma

Business Wire · 5 Aug 2026positive

Obsidian Therapeutics announced that the first patient has been enrolled in the registration-enabling cohort of the Phase 1/2 Agni-01 multicenter study evaluating amsoki-cel (formerly OBX-115), an engineered TIL cell therapy, in advanced melanoma.

Why it matters — This marks a clinical milestone for Obsidian's lead engineered TIL cell therapy candidate as it enters a registration-enabling cohort.

FAQ

Frequently asked questions about OBX stock

What is the OBX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Obsidian Therapeutics, Inc. have a median 12-month price target of $42, with estimates ranging from $32 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OBX stock a buy right now?

Of the 5 analysts covering Obsidian Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Obsidian Therapeutics, Inc. 62 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OBX?

As at 31 Oct 2026, Obsidian Therapeutics, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (100 of 100).

Will OBX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +184.0% from the last close, and Ticker Nerd's factor model ranks Obsidian Therapeutics, Inc. 62 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OBX stock forecast for 2030?

No analyst covering Obsidian Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OBX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $43 over the next 12 months.

What does Obsidian Therapeutics, Inc. do?

Obsidian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on engineered cell and gene therapies for cancer, with an emphasis on solid tumors.

What is the latest news on OBX?

The most recent item we track (Business Wire, 2 Oct 2026): "Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting". Obsidian Therapeutics announced it will present a poster of updated data from its Phase 1 first-in-human study and Phase 1/2 Agni-01 multicenter study of amsoki-cel (OBX-115) in patients with immune-checkpoint inhibitor-resistant advanced melanoma at the SITC 2026 Annual Meeting. The presentation covers patients from the single-center FIH study and the multicenter trial.

Company

About Obsidian Therapeutics, Inc.

Obsidian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on engineered cell and gene therapies for cancer, with an emphasis on solid tumors. The company develops tumor-infiltrating lymphocyte (TIL) therapies built on its proprietary cytoDRiVE platform, which is designed to control protein function using FDA-approved small-molecule drugs. Its lead program, OBX-115, is an investigational autologous TIL therapy incorporating membrane-bound IL15 to support T-cell activity, persistence, and antitumor response. Obsidian Therapeutics’ current pipeline centers on next-generation immuno-oncology treatments for advanced melanoma, non-small cell lung cancer, and other solid tumor indications. The company operates within the biotechnology sector, where its platform-based approach combines cell engineering, protein regulation, and clinical development to address difficult-to-treat cancers.

CEO Dr. Madan Jagasia M.D., M.S. · 87 employees · United States · https://obsidiantx.com